CA Patent

CA3079916A1 — Pharmaceutical composition containing quinoline derivative

Assigned to Jiangsu Hengrui Medicine Co Ltd · Expires 2019-05-02 · 7y expired

What this patent protects

The present invention provides a pharmaceutical composition containing a quinoline derivative. In particular, the present invention provides a method for preparing a pharmaceutical composition containing (R,E)-N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyqui…

USPTO Abstract

The present invention provides a pharmaceutical composition containing a quinoline derivative. In particular, the present invention provides a method for preparing a pharmaceutical composition containing (R,E)-N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-3-(1-methylpyrrolidin-2-yl)-acrylamide or a pharmacologically acceptable salt thereof. The preparation method is suitable for industrial mass production, and the resultant sample has characteristics of rapid dissolution, uniform dissolution, etc.

Drugs covered by this patent

Patent Metadata

Patent number
CA3079916A1
Jurisdiction
CA
Classification
Expires
2019-05-02
Drug substance claim
No
Drug product claim
No
Assignee
Jiangsu Hengrui Medicine Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.